Nature Cancer

Article	Citations
The impact of the COVID-19 pandemic on cancer care	358
Pan-cancer image-based detection of clinically actionable genetic alterations	324
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis	322
Circulating tumor DNA and liquid biopsy in oncology	303
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab	241
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer	233
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer	226
Cancer vaccines: the next immunotherapy frontier	201
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma	197
Overcoming therapy resistance in EGFR-mutant lung cancer	187
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	169
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	160
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	159
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome	153
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	142
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	142
Fatty acid synthesis is required for breast cancer brain metastasis	142
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	140
The metabolic landscape of RAS-driven cancers from biology to therapy	137
Cancer-associated fibroblasts in the single-cell era	134
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells	130
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells	126
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	124
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	121
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	118

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	118
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	112
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	110
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	110
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity	110
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	107
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	105
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	104
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity	101
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	101
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	99
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia	99
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	99
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	96
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort	94
The immuno-oncological challenge of COVID-19	94
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes	93
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment	92
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors	91
Applications of organoids for cancer biology and precision medicine	90
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	87
Translational advances in pancreatic ductal adenocarcinoma therapy	87
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	86
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ	86
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer	84
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	84
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	83
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	82
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	81
α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer	81
Targeting public neoantigens for cancer immunotherapy	79
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	78
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy	78
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	78
Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis	77
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	74
The cGAS–STING pathway and cancer	73
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer	73
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	73
The T cell differentiation landscape is shaped by tumour mutations in lung cancer	72
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	71
Emerging strategies for treating metastasis	71
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	71
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	70
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	68
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	68
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors	67
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	67
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	66
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2	66

Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis	65
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	64
c-Rel is a myeloid checkpoint for cancer immunotherapy	61
The present and future of PI3K inhibitors for cancer therapy	61
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response	61
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	61
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	61
CD4+ T cells in cancer	61
Dysregulation and therapeutic targeting of RNA splicing in cancer	60
Engineering-enhanced CAR T cells for improved cancer therapy	60
Crowdsourcing a crisis response for COVID-19 in oncology	59
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	58
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision	58
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors	57
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets	57
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma	55
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	55
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	54
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1	54
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer	53
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer	53
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression	52
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment	51
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain	51
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization	50
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer	49
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome	49
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	49
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma	48
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer	48
Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer	48
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study	47
The status of tumor mutational burden and immunotherapy	47
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance	47
Bystander T cells in cancer immunology and therapy	46
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	44
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity	44
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	44
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors	44
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	43
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1	43
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia	43
Accelerating precision medicine in metastatic prostate cancer	43
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	41
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	41
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors	41
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	40
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	40
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	39
Moving pan-cancer studies from basic research toward the clinic	39
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	39
The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer	39
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response	39
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells	38
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis	38
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer	38
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia	38
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	37
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response	37
Illuminating the noncoding genome in cancer	37
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma	37
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	36
Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase	36
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming	36
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia	36
The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription	36
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis	35
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	34
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression	34
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy	34
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms	34
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors	33
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy	33
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma	33
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing	33
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	32
Rethinking cancer clinical trials for COVID-19 and beyond	32
Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs	32
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia	31
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	31

Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways	31
The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries	30
Advancing Cancer Therapy	30
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer	30
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia	30
Advances in antibody-based therapy in oncology	30
Cancer cell plasticity during tumor progression, metastasis and response to therapy	30
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs	29
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors	29
Deep learning links histology, molecular signatures and prognosis in cancer	29
Zeb2 drives invasive and microbiota-dependent colon carcinoma	28
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer	28
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	28
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders	28
Delineating the evolutionary dynamics of cancer from theory to reality	28
Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth	28
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress	28
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues	27
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	27
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations	26
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer	26
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer	26
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice	26
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer	26
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations	26
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	26
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade	25
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	25
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis	25
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse	25
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling	25
Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics	25
Discovery through clinical sequencing in oncology	25
Dual ARID1A/ARID1B loss leads to rapid carcinogenesis and disruptive redistribution of BAF complexes	24
LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis	24
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia	24
Advances in ovarian cancer, from biology to treatment	24
Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma	24
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer	23
MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis	23
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1	23
Genomics-guided pre-clinical development of cancer therapies	23
ALK-positive lung cancer: a moving target	22
Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis	22
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance	22
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer	22
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	22
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	21
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response	21
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	20
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	20
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes	20
LAG-3 and PD-1 blockade raises the bar for melanoma	20
The current landscape of immunotherapy for pediatric brain tumors	20
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44	20
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	20
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity	20
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	19
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma	19
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer	19
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC	19
METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma	19
Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity	19
Envisioning the future of precision oncology trials	19
High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers	19
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	19
Starfish infers signatures of complex genomic rearrangements across human cancers	18
Immunoediting of cancer metastasis by NK cells	18
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer	17
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy	17
Missing the target in cancer therapy	17
Eliminating cervical cancer in the COVID-19 era	17
Future directions in preclinical and translational cancer neuroscience research	17
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer	17
Charting roadmaps towards novel and safe synergistic immunotherapy combinations	17
FYN–TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma	17
Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	16
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	16
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer	16
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology	16
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	16
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	16
Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells	15
Acute lymphoblastic leukemia displays a distinct highly methylated genome	15
Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade	15
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy	15
NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation	15
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy	15
A global effort to understand the riddles of COVID-19 and cancer	14
CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis	14
Sonic hedgehog accelerates DNA replication to cause replication stress promoting cancer initiation in medulloblastoma	14
Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2	14
Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity	14
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	13
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation	13